Clinical Trial Update: Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating romiplostim N01 for cancer treatment-induced thrombocytopenia in patients with leukemia; the study is currently not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Treatment-induced Thrombocytopenia
• Leukemia

Drugs mentioned

• Romiplostim N01 (romiplostim)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Cancer Treatment-induced Thrombocytopenia (CTIT) | Phase 2 | Status: NOT_YET_RECRUITING